CardiAMP cell therapy-treated patients had 37% relative risk reduction in heart death equivalent (death, heart transplant, left ventricular assist device implantation) and 9% relative risk reduction ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support ...

Please provide your email address to receive an email when new articles are posted on . Athletes with positive test for genetic heart disease but no or negligible phenotype had no cases of death or ...

Positive results from a proof-of-concept study evaluating Merck’s Winrevair pave the way for further study of the activin signaling inhibitor as a potential treatment for a subset of heart failure ...

Patients with advanced pathologic stage, a higher number of positive lymph nodes, and positive surgical margins had the highest risks of dying from prostate cancer. Lymph node positive (pN1) prostate ...

– Itovebi TM (inavolisib)-based regimen demonstrated a statistically significant and clinically meaningful benefit, reducing the risk of disease worsening or death by 57% compared with palbociclib and ...